Health Canada Patent Register guide for generic approvals
The Health Canada Patent Register lists drug patents and expiry dates. Check PM(NOC) duties and data protection before planning generic approval.
The Health Canada Patent Register lists drug patents, expiry dates and related patent information. Applicants covered by Canada's patent-linkage rules must address applicable listed rights before receiving a Notice of Compliance (NOC). But patent expiry alone does not establish an approval or launch date. See the PM(NOC) Regulations and Health Canada's warning about expiry dates.
What the register tells you
The register links medicinal ingredients with associated patents and their expiry dates. It also includes eligible certificates of supplementary protection (CSPs). Patent listing follows issuance of the relevant NOC, rather than submission filing alone. These relationships matter when checking which rights apply to a reference product and submission. See sections 3 and 4.
A blank result isn't patent clearance. Patent-list submission is optional, so the register does not contain every Canadian drug patent. Health Canada also warns that listed expiry dates cannot reliably predict generic approval or market entry. Both limits appear in its Patent Register FAQ.
How to check a reference product
Use a product-specific record rather than an ingredient match alone. The following is a practical working method, not a prescribed regulatory procedure.
- Identify the reference product. Record its ingredient, brand, strength, dosage form, route and relevant submission. These particulars help distinguish the product and submission relationships described in section 4.
- Open the official Patent Register. Read the relevant product and submission records, including their associated rights.
- Inspect the underlying Form IV where available. Older records can lack displayed information because the forms changed. Health Canada recommends checking Form IV when resolving retrieval problems in FAQ questions 7 and 8.
- Record patent and CSP expiry dates separately. A qualifying CSP can remain listed after its associated patent expires. A CSP is not an automatic two-year extension: its term is capped at two years and can be reduced. See PM(NOC) section 3 and Patent Act section 116.
- Check data protection and marketing status separately. Use the Register of Innovative Drugs and Drug Product Database.
Keep a dated copy of the records used for your assessment. Refer patent-claim interpretation and infringement questions to IP counsel rather than treating the register as a legal opinion.
How the PM(NOC) rules affect approval
The Patented Medicines (Notice of Compliance) Regulations apply to specified submissions and supplements that compare or refer to another drug. Section 5 contains marketing and patent-list conditions. It does not impose the same obligations on every pharmaceutical filing. Section 5(4) generally excludes patents added on or after the relevant filing date, and CSPs setting out those patents.
Applicants have several ways to address applicable listed rights. These include patent-owner consent, acceptance of expiry, or allegations such as invalidity or non-infringement. Litigation is not the only route. An applicant who uses the notice-of-allegation route must serve the notice and provide supporting legal and factual material under section 5.
Two clocks need careful handling:
- The patent owner or "first person" under the Regulations may bring a Federal Court action seeking a declaration of infringement. The deadline is 45 days after the day the first person is served with the notice of allegation. This clock does not start at submission filing. See section 6(1).
- The 24-month restriction on NOC issuance in section 7(1)(d) starts when that action is brought. It is conditional on the action, not automatic for every generic or biosimilar submission. See section 7.
The Court can shorten or extend that 24-month period for lack of diligence or cooperation. Other statutory qualifications also apply. Neither day 46 after service nor the end of 24 months guarantees an NOC or launch. Section 7 uses the latest applicable statutory date, subject to its qualifications.
Check the Register of Innovative Drugs separately
Health Canada data protection operates independently of patent linkage. The Register of Innovative Drugs records eligible drugs, their first NOC dates, six-year "No File" dates and data-protection end dates. It also shows pediatric-extension status. Not every branded medicine qualifies as an innovative drug under C.08.004.1.
For specified submissions based on a direct or indirect comparison with an innovative drug, the rules generally prevent filing for six years. They prevent NOC issuance for eight years. Both periods run from the innovative drug's first NOC, not its patent grant or commercial launch. A qualifying pediatric extension lengthens the approval bar to eight years and six months, without extending the six-year filing bar. See C.08.004.1(3) and (4).
Exceptions need separate assessment. The provision addresses innovative drugs not marketed in Canada and distinguishes consent to early filing from consent to early NOC issuance. Consult subsections (5), (6) and (8) before relying on an exception.
Do not add eight years to patent expiry. A submission can remain on an IP hold after data protection ends until PM(NOC) requirements are met, as Health Canada's guidance, section 3.3 explains.
Use each database for its own purpose
The NOC database supplies authorization history, not patent clearance. The Drug Product Database provides product authorization and availability information. Neither replaces the patent and data-protection checks above.
RegAffairs AI explains these distinctions in its answer on the Patent Register and generic approvals. Health Canada's FAQ expressly warns that listed expiry dates do not reliably predict market entry.